

Carolyn S P Lam

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8092300/carolyn-s-p-lam-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

21,219
citations

75
h-index

135
g-index

473
ext. papers

32,801
ext. citations

8.5
avg, IF

7.03
L-index

#	Paper	IF	Citations
382	Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
381	Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis.. <i>Heart Failure Reviews</i> , 2022 , 1	5	2
380	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , 2022 , 24, 143-168	12.3	7
379	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , 2022 , 24, 4-131	12.3	50
378	Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort.. <i>Advances in Therapy</i> , 2022 , 39, 1432	4.1	0
377	Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.. <i>Value in Health</i> , 2022 , 25, 451-460	3.3	0
376	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , 2022 , 10, 1-11	7.9	0
375	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008594	7.6	2
374	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022 , 243, 11-14	4.9	2
373	How to Incorporate Sex and Gender Into the Design of Cardiovascular Clinical Trials.. <i>Circulation</i> , 2022 , 145, 499-501	16.7	0
372	Heart Failure Subtypes and Cardiomyopathies in Women.. <i>Circulation Research</i> , 2022 , 130, 436-454	15.7	0
371	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.. <i>Circulation</i> , 2022 , 145, 693-712	16.7	6
370	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	7.9	4
369	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure.. <i>Frontiers in Immunology</i> , 2022 , 13, 817514	8.4	2
368	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
367	Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002-2019).. <i>The Lancet Regional Health - Western Pacific</i> , 2022 , 22, 100417	5	0
366	Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 857360	5.4	0

365	Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Long-Term Prognostic Implications for Death and Heart Failure.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024060	6	
364	Association of Female Menopause With Atrioventricular Mechanics and Outcomes.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 804336	5.4	0
363	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
362	A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , 2021 ,	7.9	14
361	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021094	6	2
360	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
359	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
358	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2021 ,	14.4	8
357	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e021414	6	0
356	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 108077	3.2	0
355	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1587-1598	15.1	3
354	Drug Layering in Heart Failure: Phenotype-Guided Initiation. <i>JACC: Heart Failure</i> , 2021 , 9, 775-783	7.9	4
353	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021 , 117, 2108-2124	9.9	26
352	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 648-656	12.3	5
351	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 201-211	7.9	4
350	Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans. <i>Clinical Cardiology</i> , 2021 , 44, 646-655	3.3	2
349	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1554-1563	6.1	4
348	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021 , 11, 4885	4.9	8

347	Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1431-1435	6.7	4
346	Epicardial fat in heart failure with reduced versus preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 835-838	12.3	9
345	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2021 , 10, e017932	6	1
344	Age dependent associations of risk factors with heart failure: pooled population based cohort study. <i>BMJ, The</i> , 2021 , 372, n461	5.9	11
343	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and	12.3	143
342	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 983-991	12.3	16
341	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021 , 42, 1464-1475	9.5	16
340	Machine learning versus classical electrocardiographic criteria for echocardiographic left ventricular hypertrophy in a pre-participation cohort. <i>Kardiologia Polska</i> , 2021 , 79, 654-661	0.9	1
339	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006962	5.8	3
338	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1570-1578	4.5	1
337	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	84
336	Remote monitoring and digital health tools in CVD management. <i>Nature Reviews Cardiology</i> , 2021 , 18, 457-458	14.8	5
335	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
334	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 349-359	7.9	1
333	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021 , 397, 2385-2438	40	80
332	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1313-1321	12.3	15
331	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	12.3	39
330	Statin associated lower cancer risk and related mortality in patients with heart failure. <i>European Heart Journal</i> , 2021 , 42, 3049-3059	9.5	12

329	Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3217-3225	15.1	8
328	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1477-1484	12.3	1
327	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 4442-4451	9.5	6
326	Associations of obesity and malnutrition with cardiac remodeling and cardiovascular outcomes in Asian adults: A cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003661	11.6	1
325	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. <i>JAMA Cardiology</i> , 2021 , 6, 706-712	16.2	12
324	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2960-2972	15.1	14
323	Subclinical vasculopathy and skeletal muscle metrics in the singapore longitudinal ageing study. <i>Aging</i> , 2021 , 13, 14768-14784	5.6	1
322	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	2
321	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021 , 20, 159	8.7	3
320	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1456-1461	3.3	0
319	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021 , 144, 159-169	16.7	8
318	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 142-152	15.1	17
317	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1300-1312	12.3	13
316	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2021 , 18, 284-289	2.8	1
315	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
314	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. <i>Clinical Chemistry</i> , 2021 , 67, 216-226	5.5	3
313	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 337-349	16.7	80
312	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 1203-1212	9.5	34

311	QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. <i>Cardiology Journal</i> , 2021 , 28, 166-169	1.4	1
310	Heart failure or heart success?. <i>Cardiovascular Research</i> , 2021 , 117, e29-e34	9.9	0
309	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. <i>EClinicalMedicine</i> , 2021 , 32, 100739	11.3	4
308	Scientists on the Spot: A fraction of wisdom on heart failure. <i>Cardiovascular Research</i> , 2021 , 117, e114-e115	11.5	0
307	Generalizability of HFA-PEFF and HFPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021 , 27, 756-765	3.3	5
306	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
305	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. <i>European Heart Journal</i> , 2021 , 42, 4420-4430	9.5	15
304	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021 , 144, 1489-1499	16.7	5
303	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021 , 385, 1451-1461	59.2	358
302	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
301	Singapore's health-care system: key features, challenges, and shifts. <i>Lancet, The</i> , 2021 , 398, 1091-1104	40	6
300	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021 ,	3.7	4
299	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , 2021 , 9, 653-663	7.9	1
298	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
297	Cardiovascular and Renal Outcomes with Epeglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
296	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2021 , 9, 653-662	18.1	58
295	The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. <i>Global Heart</i> , 2021 , 16, 22	2.9	3
294	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. <i>Theranostics</i> , 2021 , 11, 9243-9261	12.1	2

293	Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure. <i>JACC Asia</i> , 2021 , 1, 303-313		1
292	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. <i>Heart</i> , 2021 ,	5.1	2
291	Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1770-1780	16.7	11
290	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof-of-concept study. <i>ESC Heart Failure</i> , 2020 , 7, 4267	3.7	1
289	Heart failure with preserved ejection fraction diagnostic scores in an Asian population. <i>European Journal of Heart Failure</i> , 2020 , 22, 1737-1739	12.3	8
288	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020 , 7, 1419-1429	3.7	4
287	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020 , 318, 126-129	3.2	6
286	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
285	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2020 , 141, 1915-1926	16.7	20
284	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 606-615	18.1	37
283	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. <i>JACC: Heart Failure</i> , 2020 , 8, 359-368	7.9	7
282	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	15.1	23
281	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020 , 41, 1357-1364	9.5	20
280	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1675-1683	12.3	10
279	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020 , 382, 1883-1893	59.2	333
278	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
277	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 391-412	12.3	84
276	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. <i>European Journal of Heart Failure</i> , 2020 , 22, 1586-1597	12.3	6

275	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1956-1965	3.7	17
274	Ethnic differences in quality of life and its association with survival in patients with heart failure. <i>Clinical Cardiology</i> , 2020 , 43, 976-985	3.3	4
273	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , 2020 , 22, 1472-1482	12.3	14
272	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020 , 22, 1065-1075	12.3	17
271	Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. <i>Circulation: Heart Failure</i> , 2020 , 13, e006472	7.6	19
270	Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. <i>Circulation</i> , 2020 , 141, 540-548	6.7	69
269	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. <i>Circulation</i> , 2020 , 141, 530-539	16.7	23
268	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 834-844	12.3	13
267	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020 , 8, e411-e422	13.6	46
266	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 234-242	7.9	12
265	Circulating neuregulin1 in heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 445-455	3.7	5
264	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e014908	6	97
263	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487319899618	3.9	3
262	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. <i>ESC Heart Failure</i> , 2020 , 7, 996-1006	3.7	5
261	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 821-833	12.3	11
260	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1079-1098	6.1	41
259	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2353-2355	9.5	13
258	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020 , 15, 44	2.9	4

257	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020 , 22, 1147-1155	12.3	22
256	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 472-485	12.3	28
255	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 519-527	12.3	3
254	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 401-410	16.2	20
253	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020 , 22, 2078-2088	12.3	15
252	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. <i>Circulation</i> , 2020 , 141, 4-6	16.7	26
251	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 751-754	12.3	1
250	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 754-758	12.3	3
249	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2020 , 9, e012199	16.7	22
248	A porcine model of heart failure with preserved ejection fraction: magnetic resonance imaging and metabolic energetics. <i>ESC Heart Failure</i> , 2020 , 7, 92-102	3.7	16
247	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
246	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. <i>JACC: Heart Failure</i> , 2020 , 8, 212-222	7.9	31
245	Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2020 , 22, 646-660	12.3	15
244	Reply in response to 'Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions'. <i>European Journal of Heart Failure</i> , 2020 , 22, 385-386	12.3	
243	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. <i>JACC: Heart Failure</i> , 2020 , 8, 931-939	7.9	30
242	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1512-1521	27.4	71
241	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. <i>Circulation</i> , 2020 , 142, 2029-2044	16.7	32
240	A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. <i>Communications Biology</i> , 2020 , 3, 697	6.7	1

239	Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2240-2249	3.7	6
238	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020 , 26, 1016-1021	3.3	9
237	Victims of Success in Failure. <i>Circulation</i> , 2020 , 142, 1129-1131	16.7	8
236	Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT-IHF randomized clinical trial. <i>ESC Heart Failure</i> , 2020 , 7, 3881	3.7	9
235	The Upcoming Epidemic of Heart Failure in South Asia. <i>Circulation: Heart Failure</i> , 2020 , 13, e007218	7.6	10
234	Cardiac and renal biomarkers in recreational runners following a 21 km treadmill run. <i>Clinical Cardiology</i> , 2020 , 43, 1443-1449	3.3	2
233	Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. <i>ESC Heart Failure</i> , 2020 , 7, 2051-2062	3.7	2
232	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020 , 109, 331-338	6.1	17
231	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 898-901	12.3	25
230	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020 , 22, 1551-1567	12.3	41
229	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019 , 394, 1254-1263	40	83
228	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
227	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019 , 40, 3297-3317	9.5	379
226	Choosing a Career in Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e006026	7.6	0
225	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , 2019 , 16, e1002916	11.6	26
224	Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. <i>Heart</i> , 2019 , 105, 842-847	5.1	14
223	High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. <i>International Journal of Cardiology</i> , 2019 , 282, 93-98	3.2	6
222	A Population-wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian males-results from the Singapore Armed Forces ECG (SAFE) study. <i>Annals of Noninvasive Electrocardiology</i> , 2019 , 24, e12634	1.5	10

221	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019 , 40, 3593-3602	9.5	38
220	Cornell product is an ECG marker of heart failure with preserved ejection fraction. <i>Heart Asia</i> , 2019 , 11, e011108	1.9	5
219	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019 , 12, e005998	7.6	22
218	Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , 2019 , 12, e005855	7.6	19
217	The diabetes-atrial fibrillation paradox. <i>Heart</i> , 2019 , 105, 893	5.1	3
216	Particulate air pollution on cardiovascular mortality in the tropics: impact on the elderly. <i>Environmental Health</i> , 2019 , 18, 34	6	17
215	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. <i>JAMA Cardiology</i> , 2019 , 4, 515-523	16.2	34
214	Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. <i>European Journal of Heart Failure</i> , 2019 , 21, 685-688	12.3	5
213	Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1300-1313	15.1	44
212	Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. <i>Cardiovascular Research</i> , 2019 , 115, 1791-1803	9.9	17
211	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 306-317	7.9	54
210	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 321-332	7.9	22
209	Prediction of Survival in Asian Patients Hospitalized With Heart Failure: Validation of the OPTIMIZE-HF Risk Score. <i>Journal of Cardiac Failure</i> , 2019 , 25, 571-575	3.3	9
208	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019 , 123, 1935-1940	3	1
207	Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes. <i>European Journal of Heart Failure</i> , 2019 , 21, 688-690	12.3	4
206	Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 239-249	7.9	44
205	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 261-266	6.7	6
204	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019 , 21, 23-36	12.3	64

203	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019 , 65, 1221-1227	5.5	11
202	Heart failure around the world. <i>European Journal of Heart Failure</i> , 2019 , 21, 1187-1196	12.3	31
201	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019 , 8, e013114	6	38
200	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. <i>Lancet Public Health</i> , 2019 , 4, e406-e420	22.4	39
199	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019 , 42, 1792-1799	14.6	25
198	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
197	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
196	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
195	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. <i>Cell</i> , 2019 , 179, 736-749.e15	56.2	51
194	SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. <i>Journal of the American Heart Association</i> , 2019 , 8, e013389	6	78
193	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019 , 140, 1359-1361	16.7	4
192	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter Interatrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1912-1917	3	10
191	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2539-2550	15.1	40
190	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019 , 4, 924-937	8.7	14
189	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
188	Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 259	2.3	6
187	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019 , 82, 447-451	2.8	4
186	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1596-1604	12.3	35

185	Sex differences in heart failure. <i>European Heart Journal</i> , 2019 , 40, 3859-3868c	9.5	159
184	Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized C magnetic resonance spectroscopy study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 357-365	6.7	31
183	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019 , 40, 705-706	9.5	1
182	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 297-307	12.3	22
181	Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions. <i>European Journal of Heart Failure</i> , 2019 , 21, 311-318	12.3	9
180	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 633-640	5.9	27
179	An East-West comparison of self-care barriers in heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 615-622	4.3	4
178	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019 , 14, 197-214	2.9	33
177	Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 461-468	5	2
176	Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. <i>International Journal of Cardiology</i> , 2018 , 263, 88-93	3.2	10
175	Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2018 , 5, 570-578	3.7	16
174	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018 , 254, 203-209	3.2	9
173	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018 , 39, 1770-1780	9.5	123
172	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 279-287	3.7	4
171	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
170	Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). <i>ESC Heart Failure</i> , 2018 , 5, 344-353	3.7	14
169	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. <i>European Journal of Heart Failure</i> , 2018 , 20, 738-747	12.3	76
168	The women's heart health programme: a pilot trial of sex-specific cardiovascular management. <i>BMC Womens Health</i> , 2018 , 18, 56	2.9	6

167	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2628-2639	15.1	263
166	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 425-432 ⁴⁻¹		54
165	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 16-37	12.3	137
164	Chronic obstructive pulmonary disease and β -blocker treatment in Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 297-305	3.7	7
163	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 715-722	12.3	26
162	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 96-104	7.9	83
161	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 122, 999-1007	3	4
160	Iron deficiency in chronic heart failure: case-based practical guidance. <i>ESC Heart Failure</i> , 2018 , 5, 764-771 ^{3.7}	3.7	31
159	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
158	Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2018 , 138, 198-205	16.7	169
157	Cardiac Structural Remodeling, Longitudinal Systolic Strain, and Torsional Mechanics in Lean and Nonlean Dysglycemic Chinese Adults. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e007047	3.9	14
156	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018 , 6, e1008-e1018	13.6	67
155	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. <i>New England Journal of Medicine</i> , 2018 , 379, 1332-1342	59.2	181
154	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1035-1039	3.2	2
153	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018 , 39, 3439-3450	9.5	195
152	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 3867-3875	9.5	33
151	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1303-1311	12.3	83
150	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018 , 39, 2780-2792	9.5	155

149	LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. <i>International Journal of Cardiology</i> , 2018 , 271, 247-253	3.2	13
148	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018 , 15, e1002541	11.6	60
147	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 121, 621-627	3	7
146	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018 , 24, 177-185	3.3	36
145	Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes. <i>European Journal of Heart Failure</i> , 2018 , 20, 821-822	12.3	2
144	Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking. <i>Circulation</i> , 2018 , 137, 488-503	16.7	18
143	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 812	3.3	4
142	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
141	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018 , 138, 2763-2773	16.7	29
140	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018 , 20, 1664-1672	12.3	54
139	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e004540	7.6	18
138	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018 , 203, 25-29	4.9	15
137	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1281-1289	12.3	20
136	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. <i>JACC: Heart Failure</i> , 2017 , 5, 157-165	7.9	24
135	Differences in Presentation, Management and Outcomes in Women and Men Presenting to an Emergency Department With Possible Cardiac Chest Pain. <i>Heart Lung and Circulation</i> , 2017 , 26, 1282-1290	1.8	10
134	Asia-Pacific consensus statement on the optimal use of high-sensitivity troponin assays in acute coronary syndromes diagnosis: focus on hs-TnI. <i>Heart Asia</i> , 2017 , 9, 81-87	1.9	12
133	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	104
132	Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	9

131	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulatO in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017 , 19, 782-791	12.3	54
130	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1664-1671	12.3	124
129	Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2876-2878	15.1	10
128	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1068-1078	7.1	168
127	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulatO in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017 , 38, 1119-1127	9.5	192
126	Fussing Over the Middle Child: Heart Failure With Mid-Range Ejection Fraction. <i>Circulation</i> , 2017 , 135, 1279-1280	16.7	27
125	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	13
124	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 14-24	7.9	42
123	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. <i>JACC: Heart Failure</i> , 2017 , 5, 92-98	7.9	86
122	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. <i>Journal of Controlled Release</i> , 2017 , 247, 127-133	11.7	69
121	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017 , 19, 1651-1660	12.3	59
120	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. <i>European Journal of Heart Failure</i> , 2017 , 19, 1483-1490	12.3	29
119	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1624-1634	12.3	113
118	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017 , 19, 1569-1573	12.3	51
117	Gender-differences in the associations between circulating creatine kinase, blood pressure, body mass and non-alcoholic fatty liver disease in asymptomatic asians. <i>PLoS ONE</i> , 2017 , 12, e0179898	3.7	10
116	Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	17
115	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
114	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17058	51.1	87

113	Membrane Proteomics of Impaired Energetics and Cytoskeletal Disorganization in Elderly Diet-Induced Diabetic Mice. <i>Journal of Proteome Research</i> , 2017 , 16, 3504-3513	5.6	6
112	The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1638-1647	12.3	46
111	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. <i>European Journal of Heart Failure</i> , 2017 , 19, 1732-1735	12.3	4
110	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. <i>Scientific Reports</i> , 2017 , 7, 9193	4.9	16
109	Comparison of health state values derived from patients and individuals from the general population. <i>Quality of Life Research</i> , 2017 , 26, 3353-3363	3.7	7
108	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	14
107	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRI Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1637-1645	3.9	73
106	Medical Podcasting and : Why, How, and What Now. <i>Circulation</i> , 2017 , 136, 513-515	16.7	3
105	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	17
104	Angiotensin Receptor Neprilysin Inhibition In Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
103	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017 , 191, 75-81	4.9	23
102	Influenza-Associated Hospitalizations for Cardiovascular Diseases in the Tropics. <i>American Journal of Epidemiology</i> , 2017 , 186, 202-209	3.8	13
101	Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. <i>American Journal of Cardiology</i> , 2017 , 120, 911-916	3	17
100	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. <i>Journal of Cardiac Failure</i> , 2017 , 23, 63-71	3.3	15
99	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017 , 19, 348-356	12.3	18
98	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017 , 38, 2869-2873	9.5	64
97	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1472-1487	12.3	128
96	Light to Moderate Habitual Alcohol Consumption Is Associated with Subclinical Ventricular and Left Atrial Mechanical Dysfunction in an Asymptomatic Population: Dose-Response and Propensity Analysis. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 1043-1051.e4	5.8	27

95	Random Plasma Glucose Levels and Cardiovascular Risk. <i>JAMA Cardiology</i> , 2016 , 1, 823-824	16.2	1
94	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2217-2228	15.1	157
93	Impact of aortic root size on left ventricular afterload and stroke volume. <i>European Journal of Applied Physiology</i> , 2016 , 116, 1355-65	3.4	7
92	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. <i>JACC: Heart Failure</i> , 2016 , 4, 419-27	7.9	34
91	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. <i>JACC: Heart Failure</i> , 2016 , 4, 502-10	7.9	32
90	Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 27-40	4.3	32
89	Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort. <i>PLoS ONE</i> , 2016 , 11, e0148073	3.7	21
88	Longitudinal Community-Based Study of QT Interval and Mortality in Southeast Asians. <i>PLoS ONE</i> , 2016 , 11, e0154901	3.7	6
87	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. <i>Korean Journal of Internal Medicine</i> , 2016 , 31, 1-14	2.5	10
86	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <i>European Journal of Heart Failure</i> , 2016 , 18, 588-98	12.3	173
85	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016 , 102, 1464-71	5.1	11
84	Influence of Ethnicity, Age, and Time on Sex Disparities in Long-Term Cause-Specific Mortality After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	8
83	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016 , 22, 1-32	1.7	60
82	Heart failure with preserved ejection fraction in hypertension. <i>Current Opinion in Cardiology</i> , 2016 , 31, 410-6	2.1	23
81	Association of Age, Sex, Body Size and Ethnicity with Electrocardiographic Values in Community-based Older Asian Adults. <i>Heart Lung and Circulation</i> , 2016 , 25, 705-11	1.8	10
80	Paradoxical Low-Gradient Aortic Stenosis: The HFpEF of Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2447-2448	15.1	10
79	Racial Differences in Electrocardiographic Characteristics and Prognostic Significance in Whites Versus Asians. <i>Journal of the American Heart Association</i> , 2016 , 5, e002956	6	15
78	High-Sensitivity Sandwich ELISA for Plasma NT-proUcn2: Plasma Concentrations and Relationship to Mortality in Heart Failure. <i>Clinical Chemistry</i> , 2016 , 62, 856-65	5.5	16

77	Impact of stock market volatility on mortality and cardiovascular events. <i>International Journal of Cardiology</i> , 2016 , 223, 318-319	3.2	2
76	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , 2016 , 37, 3141-3153	9.5	97
75	Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016 , 18, 81-8	12.3	90
74	Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF). <i>ESC Heart Failure</i> , 2016 , 3, 71-76	3.7	7
73	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	12.3	37
72	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2015 , 17, 135-43	12.3	15
71	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015 , 17, 527-33	12.3	30
70	Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. <i>Journal of Molecular and Cellular Cardiology</i> , 2015 , 82, 13-21	5.8	22
69	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1668-1682	15.1	89
68	Impact of the joint association between sex, age and diabetes on long-term mortality after acute myocardial infarction. <i>BMC Public Health</i> , 2015 , 15, 308	4.1	9
67	Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 234-8	3.3	44
66	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015 , 243, 257-9	3.1	123
65	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2251-62	27.4	188
64	Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review. <i>Clinical Cardiology</i> , 2015 , 38, 621-8	3.3	49
63	Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. <i>European Heart Journal</i> , 2015 , 36, 2050-2060	9.5	89
62	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1577-88	3.8	38
61	Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 393-404	12.3	123
60	The Relationship among Carotid Artery Remodeling, Cardiac Geometry, and Serum N-Terminal Pro-B-Type Natriuretic Peptide Level in Asymptomatic Asians: Sex-Differences and Longitudinal GEE Study. <i>PLoS ONE</i> , 2015 , 10, e0131440	3.7	3

59	Electrocardiographic Criteria for Left Ventricular Hypertrophy in Asians Differs from Criteria Derived from Western Populations--Community-based Data from an Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2015 , 44, 274-83	2.8	5
58	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
57	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
56	Heart failure with preserved ejection fraction: a clinical dilemma. <i>European Heart Journal</i> , 2014 , 35, 1022-32	9.3	136
55	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231
54	What is normal in HFNEF?: The case for HFpEF. <i>JACC: Heart Failure</i> , 2014 , 2, 541-3	7.9	4
53	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
52	Physicians' Perception of the Patient Care Pathway for Acute Heart Failure in Asian Countries: Implications for Resource Allocation, Preventive Strategies and Clinical Trial Design. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014 , 22,	0	2
51	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014 , 22, 8	0	4
50	Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. <i>Journal of Hypertension</i> , 2014 , 32, 174-80	1.9	2
49	Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. <i>Chest</i> , 2014 , 146, 1274-1285	5.3	162
48	Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001699	11.6	135
47	Rationale and design of the SOLuble guanylate Cyclase stimulatOR in heArT failurE Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014 , 16, 1026-38	12.3	97
46	Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. <i>European Journal of Heart Failure</i> , 2014 , 16, 1125-32	12.3	72
45	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2281-93	15.1	313
44	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137
43	Women and Heart Failure: An Emerging Venus-Mars Concept. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 212-216	0.9	3
42	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design. <i>Journal of Cardiac Failure</i> , 2013 , 19, 156-62	3.3	47

41	Aortic root remodeling and risk of heart failure in the Framingham Heart study. <i>JACC: Heart Failure</i> , 2013 , 1, 79-83	7.9	35
40	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013 , 34, 676-83	9.5	36
39	How do patients with heart failure with preserved ejection fraction die?. <i>European Journal of Heart Failure</i> , 2013 , 15, 604-13	12.3	138
38	Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 928-36	12.3	54
37	Variable phenotype in murine transverse aortic constriction. <i>Cardiovascular Pathology</i> , 2012 , 21, 188-98	3.8	55
36	Pulmonary pressures and death in heart failure: a community study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 222-31	15.1	200
35	Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2012 , 14, 1338-47	12.3	143
34	Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. <i>American Journal of Cardiology</i> , 2012 , 109, 1494-8	3	38
33	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 571-8	7.6	129
32	Influence of sex and hormone status on circulating natriuretic peptides. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 618-26	15.1	98
31	Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. <i>American Journal of Medicine</i> , 2011 , 124, 1051-7	2.4	35
30	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011 , 29, 1829-36	1.9	18
29	Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. <i>Heart</i> , 2011 , 97, 964-9	5.1	147
28	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. <i>Human Molecular Genetics</i> , 2011 , 20, 1241-51	5.6	60
27	Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3242-9	5.6	114
26	Epidemiology and clinical course of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2011 , 13, 18-28	12.3	442
25	Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. <i>Circulation</i> , 2011 , 124, 24-30	16.7	222
24	The socioeconomics of hypertension: how \$50 000 may buy a drop in blood pressure. <i>Hypertension</i> , 2011 , 58, 140-1	8.5	13

23	Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 492-8		15
22	Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. <i>Hypertension</i> , 2010 , 55, 1143-9	8.5	24
21	Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 1479-84	9.4	72
20	Aortic root remodeling over the adult life course: longitudinal data from the Framingham Heart Study. <i>Circulation</i> , 2010 , 122, 884-90	16.7	119
19	Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". <i>Circulation</i> , 2010 , 122, 370-8	16.7	56
18	Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2010 , 3, 588-95	7.6	650
17	Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 845-54	15.1	458
16	Left ventricular function and exercise capacity. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 286-94	27.4	161
15	Age-associated increases in pulmonary artery systolic pressure in the general population. <i>Circulation</i> , 2009 , 119, 2663-70	16.7	314
14	Coronary sarcoidosis presenting as acute coronary syndrome. <i>Clinical Cardiology</i> , 2009 , 32, E68-71	3.3	19
13	Chronic Indwelling Pleural Catheters Reduce Hospitalizations in Advanced Heart Failure with Refractory Pleural Effusions. <i>Journal of Cardiac Failure</i> , 2009 , 15, S105	3.3	11
12	Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1119-26	15.1	724
11	Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 410-8	15.1	303
10	The mitral annular mid-diastolic velocity curve: functional correlates and clinical significance in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2008 , 21, 165-70	5.8	9
9	Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1193-202	15.1	106
8	Response to Letter Regarding Article, "Cardiac Structure and Ventricular-Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota" <i>Circulation</i> , 2007 , 116,	16.7	2
7	Revisiting methods for assessing and comparing left ventricular diastolic stiffness: impact of relaxation, external forces, hypertrophy, and comparators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H2738-46	5.2	15
6	Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. <i>Circulation</i> , 2007 , 115, 1982-90	16.7	393

5	Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. <i>Hypertension</i> , 2007 , 50, 503-11	8.5	59
4	The mitral L wave: a marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2005 , 18, 336-41	5.8	38
3	Comments on "The impact of SARS on medical house staff ...". <i>Journal of General Internal Medicine</i> , 2005 , 20, 973	4	1
2	Teaching cardiac auscultation without patient contact. <i>Medical Education</i> , 2004 , 38, 1184-5	3.7	7
1	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> ,	3.7	0